Coherus Biosciences traded at $8.88 this Wednesday July 6th, increasing $0.34 or 3.98 percent since the previous trading session. Looking back, over the last four weeks, Coherus Biosciences gained 14.88 percent. Over the last 12 months, its price fell by 33.73 percent. Looking ahead, we forecast Coherus Biosciences to be priced at 7.62 by the end of this quarter and at 7.02 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
LG Chem 524,000.00 18,000.00 3.56% -26.92%
Fujifilm 7,632.00 169.00 2.26% -6.89%
AbbVie 152.53 -1.40 -0.91% 30.65%
Acadia Pharmaceuticals 15.12 -0.15 -0.98% -36.92%
Aerie Pharmaceuticals 8.27 -0.21 -2.48% -45.66%
Akebia Therapeutics 0.46 0.05 12.47% -86.39%
ALKERMES 31.87 0.44 1.40% 25.03%
Alnylam Pharmaceuticals 150.00 -0.73 -0.48% -13.09%
Amgen 245.25 -1.48 -0.60% 0.83%
Amarin 1.56 -0.03 -1.89% -63.29%
Baxter International 65.11 -0.28 -0.43% -20.45%
Biogen 215.98 3.40 1.60% -39.22%
Bluebird Bio 4.82 -0.23 -4.55% -84.51%
BioMarin Pharmaceutical 86.41 0.05 0.06% 4.06%
Bristol-Myers Squibb 76.22 0.26 0.34% 13.52%
Coherus Biosciences 8.88 0.34 3.98% -33.73%
Endo International 0.54 0.02 4.56% -86.06%
Gilead Sciences 62.73 0.39 0.63% -8.24%
Horizon Pharma 82.47 -0.29 -0.35% -11.99%
Ironwood Pharmaceuticals 11.87 0 0% -3.50%
Jazz Pharmaceuticals 160.44 0.40 0.25% -12.81%
Eli Lilly 330.15 2.97 0.91% 40.00%
Merck & Co 93.13 0.49 0.53% 18.55%
Myriad Genetics 19.01 0.17 0.90% -40.69%
Pacira 57.66 -0.69 -1.18% 1.62%
Pfizer 52.75 1.11 2.15% 34.05%
Perrigo 40.73 -0.07 -0.17% -13.34%
PTC Therapeutics 42.91 -0.87 -1.99% -2.57%
Regeneron Pharmaceuticals 594.90 -1.66 -0.28% 1.54%
Revance Therapeutics 14.48 -0.25 -1.70% -55.41%
Sarepta Therapeutics 75.97 0.23 0.30% 5.53%
Teva Pharmaceutical Industries Ltd 2,656.00 0 0% -14.29%
Vertex Pharmaceuticals 291.16 2.18 0.75% 46.32%
Xencor 32.44 1.99 6.54% -4.14%
Zoetis 178.50 4.25 2.44% -9.57%

Indexes Price Day Year
USND 11362 39.61 0.35% -22.52%
US400 2279 -13.85 -0.60% -15.05%

Coherus Biosciences
Coherus BioSciences, Inc. is a commercial stage biotherapeutics company. The Company is focused on the biosimilar and immuno-oncology market primarily in the United States. The Company’s pipeline includes the four categories product candidates, Oncology pipeline, Immunology pipeline, Ophthalmology pipeline and Small Molecule pipeline. Oncology pipeline includes Toripalimab, an anti-PD-1 antibody; UDENYCA (pegfilgrastim-cbqv); CHS-305, a bevacizumab (Avastin) biosimilar. Immunology pipeline includes CHS-1420, an anti-TNF product candidate, as an adalimumab (Humira) biosimilar. Ophthalmology pipeline includes CHS-201, a ranibizumab (Lucentis) biosimilar. CHS-201, a ranibizumab (Lucentis) biosimilar. Small Molecule pipeline includes CHS-131, an oral, small-molecule drug candidate. CHS-131 is a once-daily oral drug candidate for non-alcoholic steatohepatitis (NASH) and other metabolic conditions.